A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
Michael Platten(National Center for Tumor Diseases), Wolfgang Wick(Hertie Institute for Clinical Brain Research), Daniela Schilling(National Center for Tumor Diseases), Stefan Stevanović(German Cancer Research Center), Lukas Bunse(Heidelberg University), J. Hense(Essen University Hospital), Irini Karapanagiotou‐Schenkel(German Cancer Research Center), Astrid Weyerbrock(University of Freiburg), Dennis Riehl(European Molecular Biology Organization), Antje Wick(Heidelberg University), Martin Misch(Humboldt-Universität zu Berlin), Andreas von Deimling(Heidelberg University), Inga Harting(Heidelberg University), Michael Henry Schmitt(Heidelberg University), Felix Sahm(German Cancer Research Center), Joachim P. Steinbach(Goethe University Frankfurt), Ghazaleh Tabatabai(Hertie Institute for Clinical Brain Research), Dietmar Krex, Anita Schmitt(Heidelberg University), Theresa Bunse(University of Mannheim)
Cited by 25
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
MHC ligands and peptide motifs: first listing
|Immunogenetics|1995|1.6k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k